Navigation Links
New Study Suggests Better Patient Outcomes with CYPHER,Sirolimus-Eluting Coronary Stent than with Taxus Stent in,Real-World Clinical Settings

Registry Analysis Published in Journal Heart Finds Taxus Stent, Implantation of Multiple Stents and Small Vessel Size To Be Independent Predictors of Need for Another Procedure


MIAMI LAKES, Fla., June 4, 2007 /PRNewswire via COMTEX News Network/ -- An analysis of data from the Western Denmark Heart Registry found that patients who received the CYPHER(R) Sirolimus-eluting Coronary Stent to open a clogged artery were less likely to need another procedure at that same lesion site (a clinical event called target lesion revascularization or TLR) than patients who received a Taxus Stent. The analysis was published in the June 1 issue of the journal Heart.

The authors of the analysis sought to identify risk factors for symptom- driven TLR when patients were treated with the CYPHER(R) Stent or the Taxus Stent in a real-world scenario. From Jan. 1, 2003 to May 18, 2005, 4,432 patients in Western Denmark were treated with a drug-eluting stent (CYPHER(R) Stent: 2,728 patients; Taxus Stent: 1,704 patients). Use of a Taxus Stent (odds ratio of 1.43; p=0.022), implantation of multiple stents per lesion (odds ratio of 1.62; p=0.008) and stent implantation in small vessels (odds ratio of 1.42; p=0.049) were found to be independent predictors of the need for TLR at nine months after the procedure.

"The major new finding of this study was that the use of the Taxus Stent was an independent predictor of TLR for a real-world population of patients treated with the CYPHER(R) Stent and the Taxus Stent," said Michael Maeng, M.D., Principal Investigator, from Aarhus University Hospital, Denmark.

When the lesions were divided into subgroups according to vessel size, the CYPHER(R) Stent yielded a 20 percent relative reduction of TLR in large vessels (2.4 percent versus 3.0 percent in arteries with a reference diameter equal to or greater than 2.8 mm; p=not significant) and a 40 percent relative reductio
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:9/18/2014)... Sept. 18, 2014  Decision Resources Group finds that ... factor (VEGF) agent for wet AMD, is equally likely ... as Genentech,s Lucentis, which is the standard of care ... organization (MCO) directors do not identify a clear clinical ... likely than Lucentis to be listed on tier 1 ...
(Date:9/18/2014)... -- Zacks.com announces the list of stocks featured in the ... discuss the latest news and events impacting stocks and ... include the Avanir Pharmaceuticals (Nasdaq: AVNR - Free Report ... ), Orexigen (Nasdaq: OREX - Free Report ), ... Gilead (Nasdaq: GILD - Free Report ). ...
(Date:9/18/2014)... , Sept. 18, 2014 Veterinary biologic ... Dr. Ashraf Hanna , M.D., Ph.D., and Dr. ... of Directors. Dr. Hanna is the Vice President of ... Financial Officer for the Genentech Foundation, while Dr. McCracken ... of Business Development and Licensing for Roche Pharma. ...
Breaking Medicine Technology:Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3
(Date:9/18/2014)... Amy Norton HealthDay Reporter ... single dose of a common antidepressant can quickly alter the ... The findings, reported online Sept. 18 in ... brain,s response to widely prescribed antidepressants. Experts said the hope ... depression are likely to benefit from a drug -- and ...
(Date:9/18/2014)... 18, 2014 TayganPoint Consulting Group, ... that President and co-founder John Cassimatis was named ... Winners for 2014, recognizing the region’s top healthcare ... emerging executive of the year. , The Innovation ... sciences that continue to shape the medical industry ...
(Date:9/18/2014)... breeding grounds for microbes -- don,t worry, it,s a ... years, not all microbes are bad. Many active enzymes ... beneficial to humans as an important part of our ... , Candida albicans , an opportunistic yeast pathogen ... doesn,t damage our healthy personal ecosystem. However, when our ...
(Date:9/18/2014)... elderly men should not be routinely screened for prostate ... new study led by researchers at Henry Ford Hospital., ... JAMA Internal Medicine , focused on the use ... prostate cancer., "We found that the effect of the ... in particular has been minimal at best," says Jesse ...
(Date:9/18/2014)... September 18, 2014 As testosterone ... in U.S. courts, Bernstein Liebhard LLP notes that ... U.S. Food & Drug Administration (FDA) subject prescription ... implemented, could greatly reduce their use. The joint ... Drug Advisory Committee, and the Drug Safety and ...
Breaking Medicine News(10 mins):Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 3Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 4
... -- A 2005 voluntary federal ban on the use of ... on all commercial shipping of such purchases within the United ... sell cigarettes, new research reveals. The ban was the ... private shippers, such as UPS and FedEx, made primarily to ...
... Reporter , FRIDAY, Feb. 25 (HealthDay News) -- Medical ... unique ways to solve challenging problems. But scientists can ... diseases, particularly when those methods involve animals or insects. ... team, which is studying fruit flies to help determine ...
... a rare disease and recurrent botulism even more rare. ... drug users has been on the rise and makes ... A new study published in Clinical Infectious ... examines this problem. From 1993 through 2006, 17 ...
... (HealthDay News) -- A fresh look at 19th century Mormon marriage ... offspring any one wife produced. "Although it,s great in terms ... that for every new woman added to a male,s household, the ... study author and evolutionary biologist Michael Wade, from Indiana University in ...
... HealthDay Reporter , THURSDAY, Feb. 24 (HealthDay News) ... to warn of impending dangers to human health if ... They believe the federal government, specifically the Environmental Protection ... emissions, however. "The science is unequivocal that global ...
... the 3rd International Conference on innovative approaches in Head ... colleagues at hospitals and institutes in Denmark presented results ... 7 study. The study, conducted across the country, investigated ... radiotherapy treatment for a head & neck cancer. "We ...
Cached Medicine News:Health News:Study Finds Drop in Online Sales of Cigarettes 2Health News:Seeking Alzheimer's Answers Among Fruit Flies 2Health News:Seeking Alzheimer's Answers Among Fruit Flies 3Health News:19th Century Polygamy Meant Fewer Kids Per Wife, Data Shows 2Health News:Medical Groups Warn Of Climate Change's Potential Impact on Health 2Health News:Medical Groups Warn Of Climate Change's Potential Impact on Health 3Health News:Medical Groups Warn Of Climate Change's Potential Impact on Health 4Health News:New way to identify patients at risk of dysphagia after head and neck cancer treatment 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: